Clinical trials: IPF
Inflammatory Response, Immunological Abnormality
Measurment of Interleuukin-6 at Exhaled Breath Condensate of Covid-19 Patients and Post Covid-19 Patients With Lung Fibrosis Randomized Controlled Study
COVID-19 has emerged as a global pandemic. It is mainly manifested as pneumonia which may deteriorate into severe respiratory failure.
- Conditions
- Inflammatory Response, Immunological Abnormality, COVID-19
- Trial name
- NCT05157204
- Testing
- measurment of interleukin-6 at exhaled condensate
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ministry of Health, Saudi Arabia
Idiopathic Pulmonary Fibrosis
Evolution of Lung 18FDG Uptake in Patients With Idiopathic Pulmonary Fibrosis and Receiving Pirfenidone
Idiopathic pulmonary fibrosis (IPF) is a rare and fatal lung disease characterized by unpredictable changes with variable kinetics of progression.
- Trial name
- PET-Fibrosis (NCT03692481)
- Testing
- 18FDG-PET scan
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Idiopathic Pulmonary Fibrosis
Responsiveness and MID of 4 Metre Gait Speed in Idiopathic Pulmonary Fibrosis
This study measures the 4 metre gait speed (4MGS) test in patients with Idiopathic Pulmonary Fibrosis (IPF). The investigators are interested to see whether usual walking speed in IPF patients changes following pulmonary…
- Trial name
- IPFRESP (NCT02530736)
- Testing
- 4 metre gait speed
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Idiopathic Pulmonary Fibrosis
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
The main purpose of this study was to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general.
- Trial name
- ISABELA1 (NCT03711162)
- Testing
- GLPG1690
- Where
- 132 sites in United States, Australia and 13 more
- Volunteers
- 525 people
- Sponsor
- Lakefront Biotherapeutics NV
Pneumonia, Pulmonary Fibrosis
Pulmonary Rehabilitation in Non-chronic Obstructive Pulmonary Disease Patients.
To determine the effect of pulmonary rehabilitation on pulmonary function in non-chronic obstructive pulmonary disease patients.To determine the effect of pulmonary rehabilitation on health related quality of life in non-chronic…
- Conditions
- Pneumonia, Pulmonary Fibrosis, Tuberculosis, Bronchiectasis
- Trial name
- NCT05174741
- Testing
- Conventional Chest Physiotherapy, Aerobic training Group
- Where
- Pakistan
- Volunteers
- 20 people
- Sponsor
- Riphah International University
Idiopathic Pulmonary Fibrosis
Respiratory Muscle Strength in Patients With Idiopathic Pulmonary Fibrosis
Respiratory muscle strength, dyspnea perception, physical activity and quality of life measurements will be performed and groups will be compared in two groups consisting of patients with idiopathic pulmonary fibrosis referred to…
- Trial name
- NCT03588260
- Testing
- no intervention - cross-sectional observational only
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Istanbul Medipol University Hospital
Pulmonary Fibrosis
Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)
The purpose of this study is to determine whether NAC added to prednisone, and azathioprine has a better effect on lung function, radiology and clinical condition than placebo + prednisone in combination with azathioprine after 6…
- Trial name
- IFIGENIA (NCT00639496)
- Testing
- n-acetylcysteine
- Where
- 7 sites in Belgium, France and 5 more
- Volunteers
- 184 people
- Sponsor
- Zambon SpA
Interstitial Lung Disease
Genentech Validation Tool for Pulmonary Fibrosis
Radiology is an important component of the multidisciplinary team. The primary goal of this project will be to create a tool using findings on chest computed tomography (CT) for nearly 300 patients with the most common types of…
- Trial name
- NCT04676594
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Columbia University
Lung Cancer and Idiopathic Pulmonary Fibrosis
Lung Cancer and Idiopathic Pulmonary Fibrosis : Pathological and Molecular Characterization
Retrospective inclusion of lung cancers developed in a context of idiopathic pulmonary fibrosis, diagnosed and / or treated in participating centers.
- Trial name
- K-FPI (NCT03486262)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Idiopathic Pulmonary Fibrosis (IPF)
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
This study will evaluate the impact Nintedanib Solution for Inhalation (AP02) has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF) as well as assess its safety and…
- Trial name
- AURA-IPF (NCT07194382)
- Testing
- AP02
- Where
- 49 sites in Australia, Canada and 5 more
- Volunteers
- 160 people
- Sponsor
- Avalyn Pharma Inc.
Idiopathic Pulmonary Fibrosis
Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study
The AC-055B201/MUSIC study is a Phase II study, comparing one dose of ACT-064922 (macitentan) 10 mg with placebo in patients with idiopathic pulmonary fibrosis (IPF).
- Trial name
- MUSIC (NCT00903331)
- Testing
- ACT-064992 (macitentan)
- Where
- 53 sites in United States, Australia and 10 more
- Volunteers
- 178 people
- Sponsor
- Actelion
Idiopathic Pulmonary Fibrosis
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older.
- Trial name
- NCT05321069
- Testing
- BI 1015550
- Where
- 334 sites in United States, Argentina and 35 more
- Volunteers
- 1,177 people
- Sponsor
- Boehringer Ingelheim
COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy
Study of Default Options in Advance Directives
Default options represent the events or conditions that are set into place if no alternatives are actively chosen. The setting of default options has well-established effects on a broad range of human decisions, but its influence…
- Conditions
- COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy, Idiopathic Pulmonary Fibrosis, Other Interstitial Lung Disease Without Curative Therapy
- Trial name
- NCT01817686
- Testing
- Comfort Default AD forms, Life Extension Default AD forms, Standard Default AD forms
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
Hay Fever, Asthma
Evaluating the Potential of Large Language Models for Respiratory Disease Consultations
The clinical trial aimes to evaluate multiple large language models in respiratory disease consultations by comparing their performance to that of human doctors across three major medical consultation scenarios.
- Conditions
- Hay Fever, Asthma, Acute Upper Respiratory Infection, Pulmonary Embolism
- Trial name
- EPLLMMRDC (NCT06457269)
- Testing
- Diagnosis by three human doctors, Diagnosis by ChatGPT-3.5 (with search capabilities), Diagnosis by ChatGPT-3.5 (without search capabilities)
- Where
- China
- Volunteers
- 703 people
- Sponsor
- North Sichuan Medical College
Covid19, Pulmonary Fibrosis
COVID-19 Pathophysiology of Long Term Implications
Coronavirus disease 2019 (COVID 19) is primarily a respiratory viral infection. At the time of writing this protocol, more than 25 million people have been affected globally.
- Conditions
- Covid19, Pulmonary Fibrosis, Organising Pneumonia, Thromboembolism
- Trial name
- NCT04813575
- Testing
- Cryo lung biopsies
- Where
- Saudi Arabia
- Volunteers
- 60 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Covid19
Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis
A randomized controlled trial to study the efficacy of low dose steroid for 14 days in the treatment of post-covid-19 lung infiltrates
- Trial name
- NCT04551781
- Testing
- 20 Mg Prednisone for 14 days, control
- Where
- Egypt
- Volunteers
- 450 people
- Sponsor
- South Valley University
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients
The main goal of this phase llb study is to compare the efficacy and safety of two doses of HEC585 tablets with placebo which is a look-alike substance that contains no active drug in patients with progressive fibrosing…
- Trial name
- NCT05139719
- Testing
- HEC585 dose A, HEC585 dose B
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
IDIOPATHIC PULMONARY FIBROSIS
The Role of Gastric Content Microaspirations in the Pathogenesis of Idiopathic Pulmonary Fibrosis
The pathogenesis of idiopathic pulmonary fibrosis (IPF) is debatable. Looking for an insult to lung parenchyma that generates the pathogenesis of the disease is challenging.
- Trial name
- NCT01714934
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Sheba Medical Center
Idiopathic Pulmonary Fibrosis
Homecare Integral Support Program for IPF Patients
Homecare patient support program especially designed for covering IPF patient needs, implemented for 12 months, for improving quality of life
- Trial name
- PSPi-IPF (NCT05173571)
- Testing
- Comprehensive patient support program (educational, physiotherapy, nutritional, emotional)
- Where
- Spain
- Volunteers
- 95 people
- Sponsor
- Institut d'Investigació Biomèdica de Bellvitge
Idiopathic Pulmonary Fibrosis, Lung Transplant; Complications
Pirfenidone as Bridging Therapy for Lung Transplant in Patients Suffering From Idiopathic Pulmonary Fibrosis
The diagnosis of idiopathic pulmonary fibrosis (IPF) is currently one of the most common diagnoses for patients under evaluation for lung transplantation.
- Trial name
- NCT03258801
- Where
- Austria
- Sponsor
- Dr. Christopher Lambers